Baclofen formulations and methods for making same
Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.
1. An injectable baclofen solution comprising:
baclofen in a concentration greater than 2 mg/mL; and
sulfate or phosphate in a concentration of from 5 mM to 25 mM;
wherein:
the solution has a pH between about 5.0 and 7.0; and
the solution is configured to comprise less than 1.3% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on an initial concentration of baclofen after at least 30 days of storage at room temperature.
2. The injectable solution of claim 1 , wherein the solution is sterilized and is configured to comprise 0.2% to 1.1% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on an initial concentration of baclofen after at least 30 days of storage at room temperature.
3. The injectable solution of claim 1 , wherein the solution is sterilized and is configured to comprise 0.2% to 1.1% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on an initial concentration of baclofen after at least 6 months of storage at room temperature.
4. The injectable solution of claim 1 , wherein the solution is configured to comprise 0.2% to 0.4% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on an initial concentration of baclofen after at least 6 months of storage at room temperature.
5. The injectable solution of claim 1 , wherein the baclofen is at a concentration between 2.1 mg/mL and 7 mg/mL.
6. The injectable solution of claim 1 , wherein a combined ionic strength of the solution is equivalent to the ionic strength of from about 0.1 M to 0.2 M NaCl or KCl.
7. The injectable solution of claim 6 , wherein the solution consists essentially of the baclofen, the sulfate or phosphate, NaCl, and water.
8. The injectable solution of claim 6 , wherein the solution consists essentially of the baclofen, the sulfate or phosphate, KCl, and water.
9. The injectable solution of claim 1 , wherein the sulfate is derived from Na 2 SO 4 .
10. The injectable solution of claim 1 , wherein the phosphate is derived from NaH 2 PO 4 .
11. The injectable solution of claim 1 , wherein the solution has a pH of 6.0.
12. The injectable solution of claim 1 , wherein the solution is configured to comprise 0.2% to 0.4% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on an initial concentration of baclofen after at least 30 days of storage at room temperature.
13. An injectable baclofen solution comprising:
baclofen in a concentration greater than 2 mg/mL;
sulfate or phosphate in a concentration of from 5 mM to 25 mM; and
NaCl and/or KCl;
wherein:
the solution has a pH between about 5.0 and 7.0;
a combined ionic strength of the solution is equivalent to the ionic strength of from about 0.1 M to 0.2 M NaCl or KCl; and
the solution is configured to comprise less than 1.3% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on an initial concentration of baclofen after at least 30 days of storage at room temperature.
14. The injectable solution of claim 13 , wherein the solution consists essentially of the baclofen, the sulfate or phosphate, the NaCl and/or KCl, and water.
15. An injectable baclofen solution comprising:
baclofen in a concentration greater than 2 mg/mL; and
sulfate or phosphate in a concentration of from 5 mM to 25 mM;
wherein:
the solution has a pH between about 5.0 and 7.0;
a combined ionic strength of the solution is equivalent to the ionic strength of from about 0.1 M to 0.2 M NaCl or KCl; and
the solution is configured to comprise less than 1.3% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on an initial concentration of baclofen after at least 30 days of storage at room temperature.
16. The injectable solution of claim 6 , wherein the solution consists essentially of the baclofen, the sulfate or phosphate, NaCl, KCl, and water.